These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6775584)

  • 21. [Myoclonic attacks induced by bromocriptine in Parkinsonian patients].
    Glaubman H; Rabey I; Vardi J
    Harefuah; 1979 Jan; 96(2):90-2. PubMed ID: 478382
    [No Abstract]   [Full Text] [Related]  

  • 22. [Treatment of Parkinson disease by bromocriptine in the black African].
    Ndiaye IP; Jacquin-Cotton L; Martini L
    Dakar Med; 1980; 25(2):131-5. PubMed ID: 7215100
    [No Abstract]   [Full Text] [Related]  

  • 23. Interaction between lansoprazole and bromocriptine in a patient with Parkinson's disease.
    Anglès A; Bagheri H; Saivin S; Montastruc JL
    Therapie; 2002; 57(4):408-10. PubMed ID: 12422563
    [No Abstract]   [Full Text] [Related]  

  • 24. [Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine].
    Montastruc JL; Schmitt L; Bagheri H
    Rev Neurol (Paris); 2003 Apr; 159(4):441-3. PubMed ID: 12773874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bromocriptine.
    McGregor AM
    Practitioner; 1981 Oct; 225(1360):1471-5. PubMed ID: 7329935
    [No Abstract]   [Full Text] [Related]  

  • 26. Bromocriptine.
    Sherman BM; Chapler FK
    J Iowa Med Soc; 1980 May; 70(5):209-10, 212. PubMed ID: 7189202
    [No Abstract]   [Full Text] [Related]  

  • 27. "Long term evaluation of combined treatment of Parkinson disease with L-dopa, peripheral decarboxylase inhibitors and bromocreptine".
    Caraceni T; Giovannini P; Girotti F; Parati E; Pederzoli M; Scigliano G
    Ital J Neurol Sci; 1981 Dec; 2(4):337-42. PubMed ID: 7333824
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pleuro-pulmonary changes after bromocriptine treatment of parkinsonism].
    Bøttcher J; Grøn U
    Ugeskr Laeger; 1981 Oct; 143(41):2648-9. PubMed ID: 7303288
    [No Abstract]   [Full Text] [Related]  

  • 30. Cognitive performances in parkinsonians before and after bromocriptine therapy.
    Piccirilli M; Piccinin GL; D'Alessandro P; Finali G; Piccolini C; Scarcella MG; Testa A
    Acta Neurol (Napoli); 1986 Jun; 8(3):167-72. PubMed ID: 3739763
    [No Abstract]   [Full Text] [Related]  

  • 31. [Use of bromocriptine in Parkinson diseases in low doses at a slow rate. 40 patients].
    Liaño H; López-Lozano JJ; Ramírez A; Rabes C; Pascual ML
    Arch Neurobiol (Madr); 1984; 47(3):143-50. PubMed ID: 6508478
    [No Abstract]   [Full Text] [Related]  

  • 32. [Pleuropulmonary changes during treatment with bromocriptine].
    Ugeskr Laeger; 1988 May; 150(18):1124. PubMed ID: 3368987
    [No Abstract]   [Full Text] [Related]  

  • 33. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease.
    Hauser RA; Koller WC; Hubble JP; Malapira T; Busenbark K; Olanow CW
    Mov Disord; 2000 May; 15(3):485-9. PubMed ID: 10830413
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A comparative study of the effect of bromocriptine and pergolide on Parkinson disease].
    de Yébenes JG; García-Ruiz PJ; Sánchez-Pernaute R
    Rev Neurol; 1997 Sep; 25(145):1343-5. PubMed ID: 9377286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Bromocriptine and pulmonary responses].
    Kinnunen E; Viljanen A
    Duodecim; 1989; 105(19):1614-7. PubMed ID: 2806146
    [No Abstract]   [Full Text] [Related]  

  • 36. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
    Korczyn AD; Brooks DJ; Brunt ER; Poewe WH; Rascol O; Stocchi F
    Mov Disord; 1998 Jan; 13(1):46-51. PubMed ID: 9452325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Bromocriptine in Parkinson's disease. Personal experience].
    Chacón JR; Piqueras L; Pery JM
    Arch Neurobiol (Madr); 1982; 45(5):371-80. PubMed ID: 7165448
    [No Abstract]   [Full Text] [Related]  

  • 38. [Bromocriptine - various pharmacological properties and indications for use].
    Jeske W
    Pol Tyg Lek; 1982 Jul; 37(22):653-6. PubMed ID: 7177958
    [No Abstract]   [Full Text] [Related]  

  • 39. Gynecological follow-up of parkinsonian patients on long-term bromocriptine treatment.
    Grönroos M; Salmi T; Erkkola R; Liukko P; Rinne UK
    Acta Obstet Gynecol Scand; 1985; 64(1):81-2. PubMed ID: 3976380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Improved therapeutic response to L-dopa in Parkinson's disease, when combined with bromocriptine (author's transl)].
    Ulm G
    Nervenarzt; 1981 Feb; 52(2):116-20. PubMed ID: 7219619
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.